These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Should tuberculin skin test be positive to give latent tuberculosis treatment before tumor necrosis factor-alpha inhibitors in selected patients in developing countries? Abud-Mendoza C; Martínez-Martínez MU; DE Jesús Macías-Mendoza J; Magaña-Aquino M J Rheumatol; 2010 Mar; 37(3):672-3; author reply 673. PubMed ID: 20197567 [No Abstract] [Full Text] [Related]
49. [Approved indications and other possible utilizations of anti-TNFα biologic drugs]. Grassi W; Montecucco C Reumatismo; 2005; 57(4 Suppl):30-3. PubMed ID: 16385353 [TBL] [Abstract][Full Text] [Related]
50. Tuberculin skin test conversion in patients under treatment with anti-tumor necrotizing factor alpha agents. Hejazi ME; Ahmadzadeh A; Khabbazi A; Ebrahimi A; Farmani M; Hejazi Y BMC Infect Dis; 2020 Jul; 20(1):464. PubMed ID: 32615992 [TBL] [Abstract][Full Text] [Related]
51. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Furst DE; Keystone EC; Breedveld FC; Kalden JR; Smolen JS; Antoni CE; Burmester GR; Crofford LJ; Kavanaugh A Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii2-5. PubMed ID: 11890647 [TBL] [Abstract][Full Text] [Related]
52. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis. Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290 [TBL] [Abstract][Full Text] [Related]
53. [Are there differences among anti-TNFα biological drugs?]. Valesini G Reumatismo; 2005; 57(4 Suppl):1-2. PubMed ID: 16385348 [TBL] [Abstract][Full Text] [Related]
54. [Rheumatic diseases need more attention in case of the desire to have children and during pregnancy]. de Man YA; Dolhain RJ; Steegers EA; Hazes JM Ned Tijdschr Geneeskd; 2011; 155(13):A2622. PubMed ID: 21447200 [TBL] [Abstract][Full Text] [Related]
55. Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors. Mariette X; Reynolds AV; Emery P Ann Rheum Dis; 2012 Dec; 71(12):e2. PubMed ID: 23014259 [No Abstract] [Full Text] [Related]
56. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Criscione LG; St Clair EW Curr Opin Rheumatol; 2002 May; 14(3):204-11. PubMed ID: 11981314 [TBL] [Abstract][Full Text] [Related]
57. Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. Tymms K; Littlejohn G; Griffiths H; de Jager J; Bird P; Joshua F; Nash P; Handel M; McManus H; Butcher BE; Youssef P Clin Rheumatol; 2018 Jun; 37(6):1617-1623. PubMed ID: 29667098 [TBL] [Abstract][Full Text] [Related]
58. HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis. Moghoofei M; Mostafaei S; Ashraf-Ganjouei A; Kavosi H; Mahmoudi M Microb Pathog; 2018 Jan; 114():436-443. PubMed ID: 29223453 [TBL] [Abstract][Full Text] [Related]
59. Editorial: the vital role of randomized controlled trials in Arthritis & Rheumatology. Solomon DH; Weinblatt ME; Bucala RJ Arthritis Rheumatol; 2015 Oct; 67(10):2555-6. PubMed ID: 26139424 [No Abstract] [Full Text] [Related]
60. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India - followup report. Malaviya AN; Kapoor S; Garg S; Rawat R J Rheumatol; 2010 Jan; 37(1):209. PubMed ID: 20040648 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]